Nanometrics Inc. (NANO)

33.40
0.53 1.60
NASDAQ : Electronic Technology
Prev Close 33.93
Open 33.90
Day Low/High 33.19 / 33.90
52 Wk Low/High 25.52 / 48.26
Volume 62.38K
Avg Volume 233.70K
Exchange NASDAQ
Shares Outstanding 24.69M
Market Cap 829.27M
EPS 2.40
P/E Ratio 18.77
Div & Yield N.A. (N.A)

Latest News

Chip Equipment Shares Lower After Downgrades by DA Davidson

Chip Equipment Shares Lower After Downgrades by DA Davidson

The investment firm is wary of the sector, citing stocks' year-to-date rise and other factors. But it remains bullish on the industry longer term.

Interesting NANO Put And Call Options For August 16th

Interesting NANO Put And Call Options For August 16th

Investors in Nanometrics, Inc. saw new options become available this week, for the August 16th expiration.

Nanometrics And Rudolph Technologies To Jointly Participate In The 11th Annual CEO Investor Summit 2019

Nanometrics And Rudolph Technologies To Jointly Participate In The 11th Annual CEO Investor Summit 2019

Nanometrics Incorporated (NASDAQ: NANO), a leading provider of advanced process control metrology and software analytics, and Rudolph Technologies, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Rudolph Technologies, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Rudolph Technologies, Inc.

NEW YORK, June 25, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Rudolph Technologies, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Rudolph Technologies, Inc. Acquisition

SHAREHOLDER ALERT: WeissLaw LLP Investigates Rudolph Technologies, Inc. Acquisition

NEW YORK, June 24, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Rudolph Technologies, Inc.

Nanometrics And Rudolph Announce Merger Agreement To Create A Premier Semiconductor Process Control Company

Nanometrics And Rudolph Announce Merger Agreement To Create A Premier Semiconductor Process Control Company

Nanometrics Incorporated (NASDAQ: NANO), a leading provider of advanced process control metrology and software analytics, and Rudolph Technologies, Inc.

Nordic Nanovector ASA: Share Capital Increase Registered

Nordic Nanovector ASA: Share Capital Increase Registered

OSLO, Norway, June 17, 2019 /PRNewswire/ -- Reference is made to the stock exchange notice published by Nordic Nanovector ASA (the "Company") (OSE: NANO) on 31 May 2019 where the Company announced that the board of directors of the Company had resolved to...

Nordic Nanovector Presentations At The Society Of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting

Nordic Nanovector Presentations At The Society Of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting

OSLO, Norway, June 11, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® (177Lu-lilotomab satetraxetan) and with...

Nanometrics (NANO) Shares Cross Above 200 DMA

Nanometrics (NANO) Shares Cross Above 200 DMA

In trading on Friday, shares of Nanometrics, Inc. crossed above their 200 day moving average of $31.84, changing hands as high as $32.06 per share.

Nordic Nanovector To Present Preclinical Studies With 212Pb-NNV003, A Novel CD37-specific Targeted Alpha Therapy For CLL And NHL, At TRP 2019

Nordic Nanovector To Present Preclinical Studies With 212Pb-NNV003, A Novel CD37-specific Targeted Alpha Therapy For CLL And NHL, At TRP 2019

OSLO, Norway, June 6, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with 212PB-NNV003, a novel Targeted Alpha Therapy comprising its...

Nordic Nanovector: European Patent Granted For Betalutin® Or Humalutin® In Combination With Anti-CD20 Antibodies For Treating NHL

Nordic Nanovector: European Patent Granted For Betalutin® Or Humalutin® In Combination With Anti-CD20 Antibodies For Treating NHL

OSLO, Norway, June 3, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of Betalutin® or Humalutin® in combination with anti-CD20...

Nordic Nanovector ASA: Increase Of Share Capital

Nordic Nanovector ASA: Increase Of Share Capital

OSLO, Norway, May 31, 2019 /PRNewswire/ -- Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a total number of 11,840 RSUs that were issued to them in June...

Analyst Favorites With Strong Buyback Activity: Nanometrics Ranks As A Top Pick

Analyst Favorites With Strong Buyback Activity: Nanometrics Ranks As A Top Pick

A study of analyst recommendations at the major brokerages shows that Nanometrics, Inc. is the #23 broker analyst pick among those stocks screened by The Online Investor for strong stock buyback activity.

Nordic Nanovector To Present At Redeye Pre-ASCO Seminar, Jefferies Healthcare Conference And ABGSC Oncology Seminar

Nordic Nanovector To Present At Redeye Pre-ASCO Seminar, Jefferies Healthcare Conference And ABGSC Oncology Seminar

OSLO, Norway, May 27, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor conferences during May and June:   Redeye Pre-ASCO seminar in...

Nordic Nanovector ASA - Allocation Of PSUs

Nordic Nanovector ASA - Allocation Of PSUs

OSLO, Norway, May 23, 2019 /PRNewswire/ -- The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 23 May 2019 resolved to grant 10,000 Performance Share Units ("PSUs") to a new employee under the Company's equity...

Nordic Nanovector ASA - Results For The First Quarter 2019

Nordic Nanovector ASA - Results For The First Quarter 2019

OSLO, Norway, May 23, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019.

Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances To Next Cohort

Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances To Next Cohort

OSLO, Norway, May 21, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination...

Nordic Nanovector ASA: Invitation To First Quarter 2019 Results Presentation And Webcast

Nordic Nanovector ASA: Invitation To First Quarter 2019 Results Presentation And Webcast

OSLO, Norway, May 16, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that it will report its first quarter 2019 results on Thursday, 23 May 2019.

Nordic Nanovector ASA: Allocation Of Restricted Stock Unites (RSUs) To The Board Of Directors

Nordic Nanovector ASA: Allocation Of Restricted Stock Unites (RSUs) To The Board Of Directors

OSLO, Norway, May 10, 2019 /PRNewswire/ -- Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANO) annual general meeting held on 25 April 2019 in Oslo, Norway (the "AGM").

Nanometrics Reaches Analyst Target Price

Nanometrics Reaches Analyst Target Price

In recent trading, shares of Nanometrics, Inc. have crossed above the average analyst 12-month target price of $35.50, changing hands for $36.29/share.

The Market Awaits the Fed

The Market Awaits the Fed

I am expecting Jerome Powell to be just a touch more hawkish.

Nordic Nanovector Appoints Fredrik Haavind As Head Of Legal And Compliance

Nordic Nanovector Appoints Fredrik Haavind As Head Of Legal And Compliance

OSLO, Norway, April 29, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind as the newly established Head of Legal and Compliance.

Nordic Nanovector ASA: Annual General Meeting Held

Nordic Nanovector ASA: Annual General Meeting Held

OSLO, Norway, April 25, 2019 /PRNewswire/ -- The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway.

Nordic Nanovector: Safety Review Committee Approves Advancing To Final Dosing Regimen In Phase 1 Trial Of Betalutin® In DLBCL

Nordic Nanovector: Safety Review Committee Approves Advancing To Final Dosing Regimen In Phase 1 Trial Of Betalutin® In DLBCL

OSLO, Norway, April 10, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of single-administration Betalutin® (177Lu-satetraxetan-lilotomab) in patients with...

Nordic Nanovector ASA: Notice Of Annual General Meeting On 25 April 2019

Nordic Nanovector ASA: Notice Of Annual General Meeting On 25 April 2019

OSLO, Norway, April 4, 2019 /PRNewswire/ -- Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 25 April 2019 at 15.

Nordic Nanovector ASA Publishes 2018 Annual Report

Nordic Nanovector ASA Publishes 2018 Annual Report

OSLO, Norway, April 3, 2019 /PRNewswire/ -- Nordic Nanovector ASA has today published its 2018 Annual Report, including the complete 2018 Annual Accounts with notes.

Nordic Nanovector: Promising Results From Preclinical Studies With A Novel CD37-targeted Alpha Therapy For B-cell Tumours Presented At TAT11

Nordic Nanovector: Promising Results From Preclinical Studies With A Novel CD37-targeted Alpha Therapy For B-cell Tumours Presented At TAT11

OSLO, Norway, April 2, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha therapy for B-cell tumours have been reported today in an oral...

Nordic Nanovector To Present At DNB's SME Conference And Kempen Life Science Conference

Nordic Nanovector To Present At DNB's SME Conference And Kempen Life Science Conference

OSLO, Norway, March 28, 2019 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor conferences during April: DNB's 15th Annual Small & Medium...

TheStreet Quant Rating: B (Buy)